Clinical trials recruiting for Breast cancer
2,239
Recruiting trials
51
US states with sites
85
Countries
8%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pembrolizumab | 54 |
| Fulvestrant | 51 |
| Carboplatin | 48 |
| Capecitabine | 44 |
| Cyclophosphamide | 42 |
| Paclitaxel | 39 |
| Trastuzumab | 39 |
| Letrozole | 35 |
| Abemaciclib | 34 |
| Pertuzumab | 31 |
| Docetaxel | 29 |
| Nab-paclitaxel | 27 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 251 |
| California | 243 |
| New York | 243 |
| Florida | 214 |
| Massachusetts | 164 |
| Tennessee | 143 |
| Pennsylvania | 136 |
| Ohio | 131 |
| Virginia | 131 |
| New Jersey | 129 |
| Illinois | 124 |
| North Carolina | 122 |
Top cities
New York, New York 185Houston, Texas 181Boston, Massachusetts 152Nashville, Tennessee 122Los Angeles, California 110St Louis, Missouri 93Chicago, Illinois 91San Antonio, Texas 78Philadelphia, Pennsylvania 76Fairfax, Virginia 74
Self-screener
Recruiting trials
- "Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients"
- "The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients"
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- 18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer
- 18F-FDG PET/CT Imaging for Breast Cancer
- 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis
- 3D Ultrasound Breast Imaging
- 3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer
- 4FMFES-PET Imaging of ER+ Advanced Breast Cancers
- 5 fr Ultrahypofractionated WBI and SIB for Breast Cancer With Unfavorable Characteristics
- 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
- 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
- 68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
- 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)
- 68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
- 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
- 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- 99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer
- A 3D-Printed External Breast Prosthesis for the Improvement of Patient-reported Outcomes Among Breast Cancer Patients That Underwent a Mastectomy Without Reconstruction
- A Beta-only IL-2 ImmunoTherapY Study
- A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
- A Clinical Investigation to Confirm the Ability of MammoWave in Breast Lesions Detection
- A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection
- A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
- A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
- A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients
- A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
- A Composite Assay for HER2-positive Early-stage Breast Cancer Management
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
- A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
- A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
- A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- A Manualized Post-Traumatic Growth Intervention for People With Cancer in Greece - IC-Growth
- A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship
- A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
- A Multi-center Investigation of Family Health.
- A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
- A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
- A Multicenter Cancer Biospecimen Collection Study
- A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
- A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
- A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
- A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer
- A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials
- A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors
- A New Cancer Rehabilitation Process for Chemotherapy-Induced Foot Neuropathy Using Orthopedic Devices
- A New Tool to Promote Patient's Engagement in Their Healthcare Process
- A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
- A Novel Approach in the Evaluation of Breast Masses With Doppler US
- A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts
- A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer
- A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer
- A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
- A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
- A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
- A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- A Phase 1/1b Study of IAM1363 in HER2 Cancers
- A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
- A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1
- A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
- A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
- A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers
- A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
- A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
Related conditions
Trials recruiting for Breast cancer often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Colorectal cancer 1359Triple-negative breast cancer 138Metastatic breast cancer 131Prostate cancer 1234Pancreatic cancer 870Breast Neoplasms 105Melanoma 487Ovarian cancer 118HER2-positive breast cancer 75
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Breast cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.